advancing the treatment of
cancers and autoimmune diseases
MDX-124 – the first therapy to target annexin-A1 – has shown significant single-agent anti-cancer activity, synergy with chemotherapies and potentiation of anti-PD-1 immunotherapy.
Our first-in-class therapeutic MDX-124 specifically targets annexin-A1, a protein that modulates the immune system and plays a key role in the development of many cancers and autoimmune conditions. Annexin-A1 is a novel target, yet to be exploited in any therapeutic context.
We have generated a wealth of data demonstrating the potential of MDX-124 to treat a number of major diseases. Non-clinical data published in the Nature Portfolio journal Oncogene demonstrate that MDX-124 significantly reduces cancer cell growth, inhibits migration, reduces tumour volume in vivo and tags cancer for destruction by immune cells. MDX-124 has the potential to alter the tumour microenvironment and resensitise cancer cells to therapies which were previously rendered ineffective by the negative activity of annexin-A1.
Published pre-clinical data demonstrate powerful synergy when MDX-124 is used in combination with various standard-of-care chemotherapies – including cisplatin, paclitaxel, gemcitabine and 5-FU – resulting in significantly greater cancer cell death. MDX-124 has also been shown to enhance the impact of anti-PD-1 immunotherapy, another widely used class of cancer treatment.
Phase 1b clinical data published at the European Society for Medical Oncology (ESMO) Congress 2025 show encouraging anti-tumour activity of MDX-124 with no significant toxicity.
Medannex is also developing antibody-drug conjugates (ADCs) based on MDX-124. ADCs act like biological missiles, using an antibody to deliver powerful anti-cancer drugs directly to tumours, minimising systemic toxicity. MDX-124’s highly specific targeting, excellent safety profile and tumour-shrinking activity make it particularly attractive for this approach. This exciting new platform will create a launchpad for multiple clinical studies with various payloads, the first of which will be initiated in Q4 2027.
Medannex is collaborating with several Centres of Excellence in the UK, and other clinical oncology and autoimmune experts worldwide, to ensure that we realise the full potential of our novel therapeutic approach in multiple disease indications.
Our technology is protected by a robust intellectual property portfolio which includes composition of matter patents granted in all major territories worldwide. Feedback from leading clinicians and global pharma companies has confirmed that annexin-A1 is a unique target with major therapeutic potential in both oncology and autoimmune diseases.
Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.
